Condition (MeSH)
Sclerosis
ClinicalTrials.gov lists 33 trials for Sclerosis or a narrower condition beneath it.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Trials per phase
33 of the 33 trials are tagged with Sclerosis itself; the rest are tagged with a narrower condition beneath it.
When did Sclerosis trials start? (14)
Shown in this order: most recent first, 1990 onwards. 2026 is partial: trials registered with a 2026 start date so far, not a full year.
Trials over time, by phase
- Phase 1
- Phase 2
- Phase 2/3
- Phase 4
- Not applicable
- Observational
Top of scale: 4
Trials registered with a start date in each year, 1990 onward, stacked by phase (complete years only; the current partial year is in the table's notes). The table below lists the same counts, most recent years first.
| Year | Trials started |
|---|---|
| 2025 | 3 |
| 2024 | 4 |
| 2023 | 2 |
| 2022 | 1 |
| 2021 | 2 |
| 2020 | 4 |
| 2017 | 2 |
| 2013 | 2 |
| 2011 | 1 |
| 2009 | 2 |
Showing 10 of 14 earlier years.
No forecast is made for this condition: it averages 2.0 trial starts a year over the five years to September, under the 5 a year the method needs.
Prediction, not a registry value: median of 36 months from start to primary completion across 5 trials still running at the 2026-10-09 snapshot; registered median of 31 months across 17 trials with a primary completion typed Actual. Source: ClinicalTrials.gov / AACT (CTTI), public domain.
What phase are Sclerosis trials in? (7)
Shown in this order: phase order.
Show the trials by phase as a table
| Phase | Trials |
|---|---|
| Phase 1 | 6 |
| Phase 2 | 5 |
| Phase 2/3 | 2 |
| Phase 4 | 2 |
| Not applicable | 9 |
| Observational | 7 |
| Expanded access | 2 |
How many Sclerosis trials are recruiting? (10)
Shown in this order: the order a trial moves through, from not yet recruiting to unknown.
| Status | Trials |
|---|---|
| Not yet recruiting | 1 |
| Recruiting | 5 |
| Enrolling by invitation | 1 |
| Active, not recruiting | 2 |
| Completed | 16 |
Showing 5 of 10 statuses.
Status as registered on ClinicalTrials.gov. Each trial is counted once.
Which lead sponsors run the most Sclerosis trials? (12)
Shown in this order: most trials first. Lead sponsors the registry classes as industry, NIH, US federal, other government or network. A hospital or university the registry files as government can appear here. Sponsors it classes as academic or other are shown on the full page, because that class cannot separate an institution from a named investigator.
| Sponsor | Trials |
|---|---|
| Gilead Sciences | 2 |
| Hope Biosciences Research Foundation | 2 |
| Merck KGaA, Darmstadt, Germany | 2 |
| National Institute of Allergy and Infectious Diseases (NIAID) | 2 |
| Actelion | 1 |
Showing 5 of 12 sponsors.
Which drugs are being tested for Sclerosis? (1)
Shown in this order: most trials first. One row per drug, matched to a single molecule under all its names, ranked by number of trials.
| Drug | Trials |
|---|---|
| Cytoxan | 2 |
Interventions as named in the registry (14)
Shown in this order: most trials first.
| Drug | Trials |
|---|---|
| HB- adMSCs (Hope Biosciences adipose derived mesenchymal stem cells) | 2 |
| Diosmin / Hesperidin | 1 |
| Levetiracetam XR | 1 |
| MSC-Derived Exosomes | 1 |
| N Acetyl Cysteine | 1 |
Showing 5 of 14 interventions.
These are the names sponsors entered on ClinicalTrials.gov that we have not matched to a single molecule. Some are drugs under a brand or code name; others are procedures, doses or arm labels.
Which serious adverse events do Sclerosis trials report? (10)
Shown in this order: most subjects affected first. Subjects affected summed across trials, a cross-trial signal, not a rate.
| Adverse event | Subjects affected | Trials |
|---|---|---|
| MULTIPLE SCLEROSIS RELAPSE | 21 | 1 |
| Cholangitis | 14 | 1 |
| Pneumonia | 8 | 2 |
| Abdominal pain | 7 | 2 |
| Lymphopenia | 7 | 1 |
Showing 5 of 10 adverse events.
Which publications cover Sclerosis? (104)
Shown in this order: major-topic papers first, then newest, then most linked to trials.
| Publication | Journal | Year | Major topic |
|---|---|---|---|
| Hippocampal sclerosis and temporal lobe epilepsy following febrile status epilepticus: The FEBSTAT study. | Epilepsia | 2024 | Yes |
| A Multicenter Phase II Trial of Ruxolitinib for Treatment of Corticosteroid Refractory Sclerotic Chronic Graft-Versus-Host Disease. | Journal of clinical oncology : official journal of the American Society of Clinical Oncology | 2024 | Yes |
| Longitudinal changes in clinical outcome measures in COL6-related dystrophies and LAMA2-related dystrophies. | Neurology | 2019 | Yes |
| A Randomized Phase II Crossover Study of Imatinib or Rituximab for Cutaneous Sclerosis after Hematopoietic Cell Transplantation. | Clinical cancer research : an official journal of the American Association for Cancer Research | 2016 | Yes |
| Grey and white matter abnormalities in temporal lobe epilepsy with and without mesial temporal sclerosis. | Journal of neurology | 2013 | Yes |
Showing 5 of 104 publications.
Not on this page
Not measured: delivery record.
Checked, with nothing recorded for this condition: prevalence, rare-disease identity, and sub-conditions in mesh.